Entering text into the input field will update the search result below

Onyx (NASDAQ:ONXX) shares rocket 51% to $130.98 after the company says that it's rejected a...

Onyx (NASDAQ:ONXX) shares rocket 51% to $130.98 after the company says that it's rejected a $120/share offer from Amgen (AMGN +0.6%) and that it's seeking buyers after receiving inquiries. There's no shortage of speculation about who could acquire Onyx, with Bayer (OTCPK:BAYZF), Celgene (NASDAQ:CELG), Novartis (NYSE:NVS), Bristol-Myers (NYSE:BMY), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY), Gilead (NASDAQ:GILD) and Pfizer (NYSE:PFE) all mentioned. However, Forbes' Matthew Herper notes that potential blockbuster blood-cancer drug Kyprolis has only received accelerated FDA approval, which can be revoked. Big Pharma may have wanted to await further trial results later this year amid concerns about Kyprolis' safety.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ONXX--
ONYX Pharmaceuticals, Inc.